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Purpose: We investigated the accuracy and feasibility of a system that provides transrectal needle access to the prostate
concurrent with 1.5 Tesla MRI which previously has not been possible.
Materials and Methods: In 5 patients with previously diagnosed prostate cancer, MRI guided intraprostatic placement of
gold fiducial markers (4 procedures) and/or prostate biopsy (3 procedures) was performed using local anesthesia.
Results: Mean procedure duration was 76 minutes and all patients tolerated the intervention well. Procedure related
adverse events included self-limited hematuria and hematochezia following 3 of 8 procedures (all resolved in less than 1
week). Mean needle placement accuracy was 1.9 mm for the fiducial marker placement studies and 1.8 mm for the biopsy
procedures. Mean fiducial marker placement accuracy was 4.8 mm and the mean fiducial marker placement accuracy
transverse to the needle direction was 2.6 mm. All patients who underwent the procedure were able to complete their course
of radiotherapy without delay or complication.
Conclusions: While studies of clinical usefulness are warranted, transrectal 1.5 T MRI guided prostate biopsy and fiducial
marker placement is feasible using this system, providing new opportunities for image guided diagnostic and therapeutic
prostate interventions.
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agnetic resonance imaging with an endorectal coil
has a potentially valuable role in the diagnosis of
prostate cancer. While the excellent soft tissue con-
trast and functional imaging capabilities of MRI provide
high sensitivity for detecting prostate tumors,1 the low spec-
ificity of MRI has limited its role in prostate cancer diagnosis
and staging.2 Ideally, an MRI platform that provides for
image guided prostate biopsy could maintain the sensitivity
of MRI while gaining the specificity of tissue biopsy.
Previously, prostate biopsy and brachytherapy proce-
dures have been performed using low field strength (eg 0.2
or 0.5T) open scanner architectures.3,4 While these systems
provide easier access to the patient, they do not produce the
highest quality MR images, have limited potential for func-
tional and spectroscopic imaging, and are less widely avail-
able. To improve image quality, some groups have
investigated hybrid approaches in which previously ac-
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113quired 1.5T MR images are registered to images acquired
with a lower field strength scanner, where the actual inter-
vention is performed.5,6 Others have registered previously
acquired 1.5T MR images with intraoperative ultrasound
images.7,8 While both of these image registration ap-
proaches simplify the intervention itself, registration be-
tween image sets, particularly in highly deformable organs
such as the prostate, can introduce inaccuracies.
There are currently no systems that allow for transrectal
needle placement concurrent with the acquisition of diag-
nostic quality MR images in a closed 1.5T MR scanner ar-
chitecture. An obvious application of such a system is MR
guided diagnostic prostate biopsy. However, performing
MRI guided minimally invasive therapeutic interventions is
also of interest.9 In the research setting, such a system could
provide for direct histological validation and molecular anal-
ysis of various prostate MR imaging techniques.
In this technical pilot study, we investigate the feasibility
and tissue targeting accuracy of a novel system that allows
for transrectal needle access to the prostate while a patient
is imaged inside of a closed 1.5T MRI scanner. In 5 patients
with previously diagnosed localized prostate cancer, this
device was used for 4 gold fiducial marker placement proce-
dures and 3 MRI guided prostate biopsy procedures. Al-
though not discussed, the fiducial markers were used to
guide external beam radiation therapy and the tissue biop-
sies, collected from normal and cancerous prostate tissue,
were used to study the molecular effects of radiation ther-
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ity, we do not attempt to prove a clinical role for this
device, but rather, only to study its feasibility and target-
ing accuracy.
MATERIALS AND METHODS
Interventional device. A custom made MR compatible de-
vice was designed for the interventional procedures.9,10 A 23
mm-diameter hollow endorectal sheath, placed in the rec-
tum at the beginning of the procedure, remains immobile
throughout the intervention (fig. 1, A). This sheath includes
an integrated 20 mm diameter single turn imaging coil
surrounding an anterior window that allows for needle ac-
cess to the prostate. An 18 mm diameter cylindrical needle
guide fits inside the stationary rectal sheath, contains MR
tracking microcoils (allowing for device registration), and
has a curved needle channel (allowing the needle, inserted
axially, to exit at a 36-degree angle, passing through the
rectal wall and into the prostate, fig. 1, B). The cylindrical
needle guide is mounted on a positioning stage (fig. 1, C)
which contains the mechanism that converts the rotation of
2 flexible control rods (S.S. White Technologies Inc., Piscat-
away, New Jersey, fig. 1, D), each extending to the edge of
the scanner bore, into rotation and translation of the needle
guide. Finally, the positioning stage is attached to an immo-
bilization arm mounted on a linear rail (fig. 1, D). Unless
otherwise noted, all parts of the device were fabricated from
Ultam plastic (GE Plastics, Brea, California).
Because the device has a coaxial design, the central axis
provides an open channel for needle passage. The needles
are inserted from the back of the device, pass through its
central axis, are curved within the needle guide, and emerge
from the lateral wall of the needle guide. The 18 G marker
placement needles were custom fabricated from nitinol
(MRI-Devices Daum, Schwerin, Germany). To accommodate
standard 14 gauge spring loaded MRI compatible biopsy
guns (MRI-Devices Daum), a straight needle path was
needed. Therefore, for the biopsy procedures, a needle guide
with 20 and 30-degree straight needle channels and a mod-
ified endorectal sheath were used (fig. 2).
Patient enrollment and preparation. After providing in-
formed consent, 5 patients were enrolled in an investiga-
tional protocol reviewed and approved by our institutional
review board. All patients were previously diagnosed with
clinically localized prostate cancer (via TRUS guided biopsy)
and were scheduled to receive a standard course of confor-
mal external beam radiation therapy. Four of the patients
underwent MRI guided intraprostatic placement of 4 gold
fiducial markers (4 mm long, 0.8 mm diameter, 24K gold,
Northwest Medical Physics Equipment, Lynnwood, Wash-
ington). The fiducial markers were subsequently used for
daily assessment and adjustment of external radiation beam
targeting. Three of the patients provided consent for MRI
guided prostate biopsy. Because patients were already diag-
nosed with prostate cancer, the biopsy cores (collected from
normal and cancerous prostate tissue) were used in an on-
going study of the molecular effects of radiation therapy.
Two days before and on the morning of the procedure,
patients received prophylactic antibiotics (Levofloxacin, 500
mg po 4 times daily). Because this study was designed toinvestigate the accuracy of MRI guided needle placement,
local anesthesia was administered via ultrasound guided
transrectal injection of 10 ml of 0.25% Marcaine along the
periprostatic neurovascular bundles bilaterally immediately
before the MR procedure. After the patient was positioned
prone on the scanner table, the endorectal sheath was
placed, the positioning stage was docked with the sheath,
and then the entire system was immobilized (via the 2 ball
joints and the linear rail) to prevent motion of the setup. The
patients were advanced into the scanner where scout im-
ages were collected to verify the positioning of the device
relative to patient anatomy (typically, zero or 1 positional
adjustment was necessary to achieve the proper sheath
depth).
Fiducial marker placement procedure. All interven-
tions were performed on a GE Signa Excite 1.5 T MR scan-
FIG. 1. Interventional system. A, stationary endorectal sheath
with integrated 20 mm diameter single turn imaging coil mini-
mizes tissue deformation during interventional procedure. B,
cylindrical needle guide contains MR tracking microcoils and
curved needle channel. C, positioning stage houses mechanism
that converts rotation of 2 control rods into rotation and trans-
lation of needle guide, which fits inside endorectal sheath. D,
positioning arm with 2 lockable aluminum ball joints and linear
rail allows for easy device positioning and, subsequently, rigid
immobilization.ner (GE Medical Systems). Four pulse sequences were used
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a fourth for device tracking. After the patients were posi-
tioned in the scanner and scout images acquired, T2-
weighted fast spin-echo images were acquired in the axial
and sagittal planes for visualization of the intraprostatic
and periprostatic anatomy (FSE-XL, TE 102 msec, TR 6.0
seconds, BW  20.83 KHz, ETL 16, FOV 16 cm, slice thick-
ness 3 mm, interslice spacing 0 mm, 256 x 192, NEX 3, scan
time 3:36). After acquisition, these images were automati-
cally loaded into the visualization and targeting program,
which was displayed on a screen (Da-Mat, Da-Lite Inc.,
Warsaw, IN) in the scanner room using an LCD projector
(LP340b LCD Projector, Infocus Corp., Wilsonville, Oregon,
fig. 3, B). A target for needle placement was selected and
graphically marked on these images (fig. 4).
Next, a device tracking pulse sequence was run to deter-
mine the current position of the endorectal needle guide (via
localization of the 3 tracking microcoils inside of the de-
vice).9 This 60 msec pulse sequence consists of 12, dodeca-
hedrally spaced 1D gradient echo projections (no slice
selection is used, TE 2.3 msec, TR 5.0 msec, BW 64 KHz,
FA 1o, FOV 40 cm, 256 readout points). By knowing the
position of the target, the position of the needle guide and
the needle path relative to the needle guide (determined via
a prior device calibration), the amount of rotation and trans-
lation necessary to place the target on the needle trajectory
could be calculated by the targeting program and displayed
for the operator (fig. 4). The depth of needle insertion nec-
essary to reach the target was also calculated and displayed
as part of the user interface.
As the operator moved the needle guide via the 2 control
knobs (fig. 3, A), the tracking pulse sequence was run con-
tinuously and the remaining rotation and translation re-
FIG. 2. Prostate biopsy needle guide and sheath. A, to accommoda
straight needle channels (30 degrees and 20 degrees) and modified en
was acquired with biopsy needle in place. Using 1 of 2 needle chanquired were displayed. When the needle guide was correctlypositioned, the tracking pulse sequence was stopped and the
patient table withdrawn from the scanner to allow for needle
insertion under direct supervision. To control the depth of
needle insertion, a needle stop was set, placed at the back of
the device, and the nitinol needle and cannula were intro-
duced together. Because of the impact of deformation on
tissue targeting accuracy, needles in the last 2 procedures
were inserted 5 mm past the target site and then withdrawn
back to the intended target depth before depositing the
fiducial marker. As deformation was most pronounced at the
base of the prostate, needles targeted in this area were
inserted 8 mm past the target and then withdrawn back to
the prescribed depth.
Needle position was confirmed using a T1-weighted fast
spin-echo acquisition (FSE-XL, TE 9.5 msec, TR 1.25 sec-
onds, BW 31.25 KHz, ETL 4, FOV 16 cm, slice thickness 3
mm, interslice spacing 0 mm, 256x256, NEX 1, scan time
1:20). A fiducial marker was then placed using the nitinol
stylus and a cannula withdrawal technique, as described
previously,9 and the prostate was imaged using a T2*-
weighted gradient-echo pulse sequence (GE, TE 15 msec, TR
467 msec, BW 15.6 KHz, FA 30 degrees, FOV 16 cm, slice
thickness 3 mm, interslice spacing 0 mm, 256x256, NEX 1,
scan time 2:00). Because pure gold fiducial markers produce
little susceptibility artifact and therefore little signal void,11
it was necessary to use T2*-weighting to robustly visualize
the fiducial markers. Following imaging of the fiducial
marker, another target was selected (using the T2-weighted
fast spin-echo images), and the needle/marker placement
procedure repeated.
After placement of the 4 gold markers, patients were
removed from the scanner suite and observed in the hospital
until they successfully voided without difficulty. One week
4 gauge spring-loaded biopsy guns, modified needle guide with 2,
ctal sheath were used. B, sagittal T1-weighted fast spin-echo image
all sites within prostate could be accessed.te 1
dore
nels,following the procedure, all patients were interviewed
dge
targ
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hematochezia, urinary retention, infection, and rectal dis-
comfort).
Biopsy procedure. Patient preparation and scan room
setup for the 3 MRI guided prostate biopsy procedures was
identical to that described for the fiducial marker proce-
dures. Targets were selected using axial T2-weighted fast
spin-echo images and needle location was confirmed using
FIG. 3. MR scanner room setup. A, flexible control rods (2) extend to e
while prostate is located at scanner isocenter. B, image display and
FIG. 4. Image display and targeting application. Target (white circle
ing to region cancerous tissue) in left posterior lobe of prostate. Int
as axis of needle guide (white square) are also shown. As device is moved
time.axial T1-weighted fast spin-echo images (as described). Five
14G needle core biopsies were performed in each of 3 proce-
dures.
RESULTS
Five patients were enrolled in the study, all of whom com-
pleted the protocol. With these patients, 4 fiducial marker
of scanner bore, allowing for rotation and translation of needle guide
eting application is projected onto screen in scanner room.
raphically selected within diffuse, low intensity region (correspond-
tion of image plane and projected needle path (white cross) as well) is g
ersec, targeting commands and projected needle path are updated in real
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formed. The average patient weight and height were 88 kg
and 173 cm while the maximum weight and height were 132
kg and 183 cm. Average patient age was 69 years (range 57
to 80). No patients had undergone prior radiation therapy,
prostatectomy, hormone suppression therapy or transure-
thral prostate resection.
Average total duration for the MR procedure was 76
minutes (maximum 93, minimum 60), and the average time
required for each of the 4 fiducial marker placements was 13
minutes including time for target selection, needle place-
ment, fiducial marker deposition and all confirmatory imag-
ing. Before each procedure an additional 15 minutes was
required for administration of local anesthesia and 15 min-
utes for patient positioning.
The major patient complaint during the procedure was
shoulder discomfort due to hyperextension of the joint when
lying prone on the scanner table (this was relieved in later
studies by using extra foam supports for the chest, which
reduce the shoulder angle). Following the intervention, pa-
tients were observed for an average of 2 hours until success-
fully voiding without difficulty. During the 1 week followup
2 patients experienced hematuria – 1 had a single episode
and the other had hematuria of 2 days duration, which then
resolved spontaneously. One patient reported a single epi-
sode of hematochezia. None of the patients experienced rec-
FIG. 5. Targeting, needle and fiducial-marker visualization images
during fiducial-marker placement procedure. Column 1, targets are
is visualized in axial, T1-weighted FSE images. Column 3, marker v
there is minimal tissue motion throughout each procedure.tal pain, urinary retention, infection, or other adverseevents. All patients were free of symptoms at the end of the
1 week followup.
Intra-procedure imaging. In figure 5, column 1, typical
T2-weighted fast spin-echo images acquired for target selec-
tion are shown. To improve visualization in and around the
prostate, all images were intensity corrected, producing uni-
form signal images, as described previously.12 With the nee-
dle in place, the prostate was imaged again using a T1-
weighted fast spin-echo sequence, allowing for confirmation
of needle placement accuracy (fig. 5, column 2). After each
gold fiducial marker was deposited, T2*-weighted axial im-
ages were acquired to confirmmarker location (fig. 5, column
3).
Needle and fiducial marker placement accuracy.
Needle and fiducial marker placement accuracy were mea-
sured using the axial images acquired during the procedure.
Needle accuracy was the absolute distance between the tar-
get location and the center of the needle tip bloom (measured
using the 3 dimensional coordinates from the MR image
volume). Fiducial marker placement accuracy was the abso-
lute distance between the target point and the center of the
marker void. The mean needle placement error was 1.9 mm
(range 0.3 to 3.6, fig. 6, A). The mean fiducial marker place-
ment error was 4.8 mm (range 1.9 to 8.3, fig. 6, B). The mean
ges from 2 patients (A and B, respectively), show images acquired
cted on axial, T2-weighted FSE images. Column 2, needle tip void
visualized on axial, T2*-weighted gradient-echo images. Note that. Ima
sele
oid isfiducial marker placement error transverse to the needle
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tissue biopsy cores are typically 1.5 cm long, transverse
error measurements are more relevant for assessing the
accuracy of the system for collecting tissue samples.
Biopsy needle placement accuracy. Three MR guided
prostate biopsy procedures were performed. Biopsy locations
were selected throughout the peripheral zone of the prostate
using T2-weighted fast spin-echo images (fig. 7, A). Subse-
quently, after inserting the biopsy needle but before collect-
ing the tissue core biopsy, T1-weighted fast spin-echo
images were acquired to confirm biopsy needle placement
accuracy (fig. 7, B and C). A total of 15 tissue biopsies were
collected. Mean biopsy needle placement accuracy was 1.8
mm (range 0.4 to 4.0), which was similar to the accuracy
obtained using the fiducial marker placement needles. Bi-
opsy cores showing normal and cancerous prostate tissue
were collected and, as all patients were already diagnosed
with prostate cancer, were used for studies investigating the
molecular effects of radiation therapy.
DISCUSSION
Tissue targeting accuracy was measured by comparing the
location of the gold fiducial markers, deposited in the tissue,
after the needle had been removed. Assuming that the tissue
returns to its original shape after the needle is withdrawn,
the location of the deposited fiducial marker relative to the
target point gives an accurate measure of tissue targeting
accuracy. This assumption was confirmed by comparing im-
ages of the prostate acquired before and following needle
placements (fig. 8).
As expected, the prostate was elastically deformed while
the needle was within the tissue. The majority of markers
were deposited in the tissue proximal to the target location
(as measured along the needle insertion axis). As described,
the needle and cannula were inserted 5 mm past the target
point (8 mm at the prostate base) in the last 2 procedures in
an effort to minimize the impact of tissue deformation. This
technique notably improved fiducial marker placement ac-
curacy, and average marker placement accuracy for the 4
procedures was 5.9, 5.1, 4.7 and 3.5 mm, respectively. Im-
provements in patient positioning, which helped to immobi-
lize the prostate, also contributed to this accuracy
improvement. In particular, downward pressure was ap-
plied to the device before locking it into place, which immo-
bilized the prostate against the pubic symphysis.
An alternative explanation for the fiducial marker place-
ment errors is that the markers were not accurately depos-
ited at the tip of the cannula or that they were suctioned
back as the cannula and stylus were withdrawn from the
tissue. Both prior experience with this deposition technique9
and experiments performed in clear polyacrylamide gel
phantoms (results not shown) do not support this explana-
tion.
As we are ultimately interested in the accuracy with
which tissue samples can be acquired from the prostate, the
transverse component of fiducial marker placement error
was also examined (ie perpendicular to the needle insertion
axis, fig. 6, C). Commonly, core tissue biopsies are 15 mm
long and approximately 1.5 mm in diameter. Therefore,
because the tissue core is so long, small errors in theinsertion depth of the biopsy needle are not of great con-
sequence.
As all of our patients were already diagnosed with pros-
tate cancer, biopsy cores were processed for studies examin-
ing the molecular effects of radiation therapy. While the
present study has allowed us to establish the accuracy of MR
guided needle placement and tissue targeting accuracy, we
cannot yet comment on the overall, histologically validated
sensitivity and specificity of MR guided diagnostic biopsy
using this device. Subsequent studies with larger numbers
of patients will be required to answer this question and must
deal with confounding factors such as patient tumor size,
FIG. 6. Needle and fiducial-marker placement accuracy shown by
error histograms for all 16 gold fiducial markers placed. A, needle
tip location errors. B, fiducial marker location errors. C, fiducial
marker in-plane location errors. Mean placement errors for each
are 1.9, 4.8 and 2.6 mm, respectively. Because tissue core biopsies
are typically 1.5 cm long, last measure, fiducial marker in-plane
placement error, is best predictor of tissue biopsy acquisition
accuracy.patient selection (ie only patients in whom TRUS guided
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guided biopsy), and the sensitivity/specificity of the MR im-
aging sequences used. Moreover, as this technique is much
more expensive and time consuming than TRUS guided
prostate biopsy, its clinical usefulness remains to be estab-
lished. Nevertheless, the application of this device for inves-
tigational image guided interventions can be foreseen.
CONCLUSIONS
We emphasized 4 key features of the system investigated in
this study. First, the entire device is compact and, therefore,
can be used in a standard 1.5 T cylindrical scanner archi-
tecture, even with larger patients (the largest patient
treated was 132 kg, 4 kg less than the manufacturer limit for
the scanner table). As standard scanner architectures are
much more widely available than open models, this system
could be applicable at many centers and moreover, can im-
mediately take advantage of mainstream MRI hardware
and pulse sequence development (such as the introduction of
3.0T whole body scanners). Second, the needle placement
procedure is uncomplicated in that 4 targeted needle place-
ments can be performed with an overall MR procedure time
of approximately 1 hour (including time for confirmatory
imaging after every needle and fiducial marker placement).
Third, the endorectal sheath, which includes the local imag-
FIG. 7. Biopsy target and needle visualization images. A, biopsy loc
C, 14 gauge biopsy needle void is visualized in axial, T1-weighted f
FIG. 8. T1-weighted axial fast-spin-echo images of prostate. A, acq
procedure. C, 50 minutes after start of procedure. Throughout interventio
remain stable. Importantly stationary endorectal sheath prevents moveing coil and entirely contains the needle guide, remains
stationary throughout the procedure. This design helps to
prevent deformation of the prostate and surrounding tissues
during the procedure, maintaining accurate registration of
all image data sets and reducing the need for deformable
registration techniques.13 Also, it prevents distention of the
rectal wall during needle guide positioning, improving pa-
tient comfort. Finally, we do not rely heavily on real time
imaging techniques. Other than the device tracking pulse
sequence, no specialized pulse sequences are required when
using this device. Therefore, we maintain the flexibility to
use virtually any imaging technique, including MR spectros-
copy and dynamic contrast enhancement, both of which have
shown promise in the diagnosis and delineation of tumors
within the prostate. Currently, we have focused on anatom-
ical imaging techniques. Subsequent work will investigate
the application of the device with pulse sequences that pro-
vide information about the functional and metabolic state of
the tissue.
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Abbreviations and Acronyms
BW  bandwidth
ETL  echo train length
FA  flip angle
FOV  field of view
FSE  fast spin echo
GE  gradient echo
MRI  magnetic resonance imaging
NEX  number of excitations
T1  longitudinal relaxation time
T2  transverse relaxation time
TE  echo time
TR  repetition time
TRUS  transrectal ultrasound
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